Please login to the form below

Not currently logged in
Email:
Password:

chronic lymphocytic leukaemia

This page shows the latest chronic lymphocytic leukaemia news and features for those working in and with pharma, biotech and healthcare.

Roche reveals four-year follow-up data for Venclyxto in CLL at EHA2021

Roche reveals four-year follow-up data for Venclyxto in CLL at EHA2021

This analysis showed that the chemotherapy-free Venclyxto (venetoclax) plus Gazyvaro (obinutuzumab) regimen had an estimated PFS rate of 74% in previously untreated patients with chronic lymphocytic leukaemia (CLL) compared to ... In another post-hoc

Latest news

More from news
Approximately 13 fully matching, plus 121 partially matching documents found.

Latest Intelligence

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    3. Novartis’ OMB-157 is a monthly or 12-weekly subcutaneous formulation of the anti-CD20 monoclonal antibody Arzerra (which is indicated as an intravenous infusion for chronic lymphocytic leukaemia) in ... 4. Vadadustat is an inhibitor of

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    as myelodysplastic syndrome (MDS), acute lymphoblastic leukaemia (ALL), chronic myeloid leukaemia (CML) and solid tumours. ... are ineligible for intensive chemotherapy, to go along with its existing indications in chronic lymphocytic leukaemia (CLL).

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Tecentriq (for the treatment of urothelial carcinoma, only approved in the US), and Venclexta (for the treatment of chronic lymphocytic leukaemia, approved in the EU and US).

  • Deal Watch June 2016 Deal Watch June 2016

    Paying $150m upfront Novartis gains access to XmAb14045 being developed for acute myeloid leukaemia (AML) and XmAb13676 in development for B-cell malignancies. ... on B-cell tumor cells, including chronic lymphocytic leukaemia (CLL) and non-Hodgkin

  • Astellas: Ten years young Astellas: Ten years young

    Meanwhile, the company has Levact (bendamustine) for chronic lymphocytic leukaemia, non-Hodgkin's lymphomas and multiple myeloma, giving it broader interests in the area.

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest from PMHub

  • Highlights in haematologic malignancy from ASH 2018

    chronic lymphocytic leukaemia and relapsed B-cell ALL. ... The course of MDS is highly variable, and around one-third of patients develop acute myeloid leukaemia (AML).

  • Therapy Watch expands oncology and IBD portfolios

    This month Therapy Watch expands its portfolio with the launch of several new trackers across numerous therapy areas including the launch of a new Chronic Myelogenous Leukaemia (CML) study in the ... Therapy Watch CML is part of a wider oncology

  • Therapy Watch expands its oncology portfolio

    Therapy Watch SCCHN is part of a wider portfolio which covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer (PCa), Renal

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...